Claturafenib
Claturafenib (PF-07799933) is an orally active inhibitor of pan-mutant BRAF. Claturafenib inhibits pERK in cells (IC50 value of 1.6 nM in HT29 cells) . Claturafenib has anticancer activity against BRAFG469A mutant NSCLC and BRAFK601E mutant melanoma[1].
Product Specifications
CAS Number
[2754408-94-9]
Product Name Alternative
PF-07799933; ARRY-440
UNSPSC
12352005
Target
PERK; Raf
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/claturafenib.html
Concentration
10mM
Purity
99.95
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C2=C(C=CC(NC3=C(Cl)C(NS(=O)(N4CC(C4)F)=O)=CC=C3F)=C2Cl)N=CN1C
Molecular Formula
C18H15Cl2F2N5O3S
Molecular Weight
490.31
References & Citations
[1]Rona Yaeger, et al. A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation. Cancer Discov. 2024 Sep 4;14 (9) :1599-1611.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
